Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).
The combined oral contraceptive Zoely® (Merck, Sharp, and Dohme Limited) has been licensed in Europe since 2011 and will be available in the UK from May 2013. Zoely will be the second UK combined oral contraceptive (COC) to contain estradiol and to be formulated as an extended regimen since the introduction of Qlaira® (Bayer plc.)
This document provides standards for resuscitation in sexual and reproductive health service settings. This document should be used in conjunction with national guidelines from other relevant professional bodies and locally agreed policies and procedures. It is important that each service identifies the level of equipment and training needed to deal with common emergencies on the basis of a local risk assessment.
These Standards are recommended for organisations providing contraceptive/sexual and reproductive health (SRH) services, including pregnancy planning, pregnancy choices, abortion, prevention and treatment of sexually transmitted infections (STIs), as well as sexual wellbeing and health promotion.
This statement provides guidance on contraceptive options for women with prolactinoma
FSRH Clinical Guideline: Management of Vaginal Discharge in Non-Genitourinary Medicine Settings (February 2012), Lapsed Guideline
Please note, this guidance document has lapsed. Up to date guidance on this topic can be found at: http://www.rcgp.org.uk/clinical-and-research/clinical-resources/sexually-transmitted-infections-in-primary-care.aspx
NICE supports the use of hysteroscopic sterilisation provided that normal arrangements are in place for clinical governance and audit.
Please note this item was archived in June 2012
Statement from the FSRH Clinical Standards Committee, the Clinical Effectiveness Committee and the Associate Members’ Working Group on the prescription, administration or supply of Contraceptive Medicines for use outside the terms of their licences Dec 09
The above committees have agreed that Clinical Effectiveness Unit Guidance on use of contraceptives is guidance on “common practice” and “current practice” in the use of these medicines and devices. Therefore it is recommended that it may not be necessary for clinicians to document every occasion when a contraceptive preparation is prescribed outside the product licence if such use falls within current guidance issued by the Faculty’s Clinical Effectiveness Unit.
Emergency Contraception - This document may have been updated since initial publication.